Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.
about
Prostate cancer biomarkers: Are we hitting the mark?Prognostic outlier genes for enhanced prostate cancer treatment.Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical ProstatectomyA reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasisUrinary continence recovery after radical prostatectomy - anatomical/reconstructive and nerve-sparing techniques to improve outcomes.Current Management Strategy for Active Surveillance in Prostate Cancer.The very-high-risk prostate cancer: a contemporary update.The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment.Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping.Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes.PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic riskCharacterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases.[Molecular biomarkers and prognostic factors for prostate cancer].Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence
P2860
Q28071654-64407497-6ABE-418C-8119-6FAE7027CAF1Q30244674-6C65BCF6-981B-4438-BD0C-3D1389EAA9A8Q35885756-F5CB28F3-7B1A-4761-B4CC-97E3AD033D4FQ36314809-DFD26409-478E-487C-A32D-EB944189851AQ37029385-6302E058-D0BF-4171-944B-A868517753DDQ37070927-77F398EB-A67C-4743-B711-72880DFB93E8Q38893692-B10A2AE1-0D35-43CA-AE33-D5FBE1F6EBA5Q38950908-749EDD44-9F09-4B03-8F3A-537C9F8BA195Q38952181-139B1EC0-1672-4A3E-B450-4F2C3A70D509Q38982680-CAEE0325-367F-4BAF-BBFD-CE820A53D75CQ38988252-A6B004AE-FB3C-4A7A-9884-445AFD5E3829Q38989776-3A09BBC8-726F-4686-82FD-0C5FA0B6ACD4Q39108592-F05CDCCC-3281-4DD4-82EB-BC7CC34FFEF9Q40356316-B31B27C2-05C8-4204-9889-B13CC8BC7D53Q40674443-A82244DA-C1D6-4FE5-8E43-6DFE51ACC25CQ42290038-957C049D-9685-4BFE-B30B-EB47168CD64DQ43533918-33465EF7-FC91-4260-850B-18DE2095B56CQ47212637-9080E8D2-11C9-4C6B-848C-8E2B6F766645Q53251387-977CA0BB-B1BA-4C53-AFA5-D9F4F1EDD133Q58788279-770DDBDC-1D25-41EB-AC30-41A479D1397B
P2860
Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Which, when and why? Rational ...... in localized prostate cancer.
@en
type
label
Which, when and why? Rational ...... in localized prostate cancer.
@en
prefLabel
Which, when and why? Rational ...... in localized prostate cancer.
@en
P2093
P2860
P356
P1476
Which, when and why? Rational ...... in localized prostate cancer.
@en
P2093
A V D'Amico
S J Freedland
P2860
P2888
P356
10.1038/PCAN.2015.31
P577
2015-06-30T00:00:00Z